Benzalkonium chloride for use in treating conjunctivitis and/or covid-19
AssigneeBausch + Lomb Ireland Limited
InventorsPatrick MCCORMICK, Kimberly MILLARD
Life of this patent
Estimating the term…
Abstract
Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.
Claims20
1-72. (canceled)
A method for treating at least one ocular manifestation of coronavirus disease 2019 (COVID-19) comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride and besifloxacin.
A method for reducing a risk of SARS-COV-2 ocular transmission comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride and besifloxacin.
A method for reducing an ocular SARS-COV-2 viral load comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride and besifloxacin.
Dependencies are inferred from the claim text.